首页/数据集/Inhibiting KRAS G12C with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS G12C and immune checkpoint inhibitor therapy. Hirade et al.

Inhibiting KRAS G12C with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS G12C and immune checkpoint inhibitor therapy. Hirade et al.

Mendeley Data2026-04-09 收录

KRAS靶向治疗

Westernblot实验验证

数据链接：

https://data.mendeley.com/datasets/29ww4s2sp4/1 数据链接链接失效反馈

官方服务：

资源简介：

Uncropped image of the Western blots

应用场景：

非小细胞肺癌分子机制

KRAS靶向治疗

Methylation of KRAS by SETD7 promotes KRAS degradation in non-small cell lung cancer

integrated proteome resources100

Supplementary Table S4 from Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy

合成致死筛选

KRAS靶向治疗

Supplementary Table S4 MaGeCK analysis of MRTX-849/TNO155 CRISPR/Cas9 screens of NSCLC cell lines

Figshare2023-12-15 更新60

Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of Cancer Cells Treated with the KRAS G12D Inhibitor MRTX1133

KRAS靶向治疗

单细胞蛋白质组学

Mutations in KRAS are common drivers of human cancers and are often those with the poorest overall prognosis for patients. A recently developed compound, MRTX1133, has shown promise in inhibiting the

NIAID Data Ecosystem30

Solution structures of full-length K-RAS bound to GDP

蛋白质结构解析

KRAS靶向治疗

Solution structures of full-length K-RAS bound to GDP Descriptor: Isoform 2B of GTPase KRas Authors: Sharma, A.K, Maciag, A.E. Deposit date: 2020-12-09 Release date: 2022-06-15 Last modified: 2025-05-

Protein Data Bank Japan2025-05-28 更新70

Cellular States Dictate Adaptive Signaling Responses to KRASG12C Inhibition: Drug Response pY Profiling

KRAS靶向治疗

肿瘤耐药信号通路

Covalent inhibitors of KRASG12C (KRASi) hold considerable progress for tumors driven by this oncogene yet early studies suggest rapid mechanisms of adaptive resistance that appear cell type dependent.

NIAID Data Ecosystem50

Inhibiting KRAS G12C with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS G12C and immune checkpoint inhibitor therapy. Hirade et al.

资源简介：

相关数据集